KELIM评分作为晚期高级别浆液性卵巢癌患者新辅助治疗反应预测因子的验证
本研究回顾性验证KELIM评分在晚期高级别浆液性卵巢癌(HGSC)接受新辅助化疗(NACT)患者中预测减瘤结局、铂敏感性、无进展生存(PFS)和总生存(OS)的作用。217例患者中,KELIM<1者中位PFS、铂类无治疗间期(PFI)和5年OS均低于KELIM≥1者,调整后疾病进展和死亡风险更高。KELIM评分有助于预测化疗反应并辅助治疗决策。
要点
- KELIM<1患者中位PFS为13.58个月,KELIM≥1者为19.69个月(p<0.001)。
- KELIM<1患者5年OS为57%,KELIM≥1者为72%(p=0.0140)。
- 调整后KELIM<1者疾病进展HR=1.57(95%CI 1.08-2.28),死亡HR=1.99(95%CI 1.01-3.95)。
核心结论
- 晚期HGSC接受NACT且KELIM<1的患者较KELIM≥1者更可能为铂耐药疾病,PFS和OS更差。
- KELIM评分可作为预测化疗反应和辅助治疗决策的有用工具。
研究设计与样本
- 回顾性队列研究,纳入2010年1月1日至2019年12月31日诊断的III-IV期HGSC并接受NACT的患者。
- KELIM评分使用化疗前100天内至少3次CA-125值计算。
- 共217例患者符合纳入标准,中位随访28.93个月(范围2.86-135.06)。
- 研究经当地伦理委员会批准。
主要发现
- KELIM≥1与<1两组在分期、功能状态、减瘤结局或BRCA状态(胚系或体细胞)方面无显著差异。
- KELIM<1患者中位PFS为13.58个月,KELIM≥1者为19.69个月(p<0.001)。
- KELIM<1患者中位PFI为7.66个月,KELIM≥1者为13.64个月(p<0.001)。
- KELIM<1患者5年OS为57%,KELIM≥1者为72%(p=0.0140)。
- 调整分期、治疗延迟、贝伐珠单抗或PARP抑制剂使用及BRCA状态后,KELIM<1者疾病进展HR=1.57(95%CI 1.08-2.28),死亡HR=1.99(95%CI 1.01-3.95)。
临床怎么用
- 作者认为KELIM评分可作为预测化疗反应和辅助治疗决策的有用工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study is to externally validate the KELIM (rate of elimination of CA-125 elimation) score in patients with high grade serous ovarian cancer(HGSC)undergoing NACT and determine its relation to outcome of cytoreduction, platinum sensitivity, progression free(PFS) and overall survival(OS). METHODS: This is a retrospective cohort study of patients with Stage III-IV HGSC diagnosed between January 1, 2010 and December 31, 2019 and treated with NACT. KELIM score was calculated using at least 3 CA-125 values within the first 100 days of chemotherapy. Demographic parameters were collected and Kaplan Meier survival analyses were performed for PFS and OS. This study was approved by local ethics board. RESULTS: 217 patients met inclusion criteria. Median follow-up was 28.93 months(range 2.86-135.06). There was no significant difference in stage, functional status, cytoreductive outcome or BRCA status(germline or somatic) between patients with a KELIM ≥ 1 and <1. Patients with a KELIM<1 had a lower median PFS (13.58 vs 19.69, p < 0.001), median platinum free interval(PFI) (7.66 vs 13.64, p < 0.001) and 5-year OS (57% vs 72%, p = 0.0140) compared to patients with KELIM≥1 . After adjusting for stage, treatment delays, bevacizumab or poly adenosine diphosphate-ribose polymerase(parp)-inhibitor use, and BRCA status, patients with KELIM<1 had a high risk of disease progression(HR = 1.57 (95% CI 1.08-2.28) and death(HR = 1.99 (95% CI 1.01-3.95) compared to KELIM≥1. BRCA status was independently associated to an increase on KELIM score (OR = 1.917, 95% CI 1.046-3.512, p = 0.035). CONCLUSION: Patients with advanced HGSC undergoing NACT with a KELIM <1 were more likely to have platinum-resistant disease, worse PFS and worse OS when compared to patients with KELIM≥1. The KELIM score can be a helpful tool to predict chemo-response and aid in treatment decision making.
引用
- Piedimonte S, Kim R, Bernardini MQ, et al. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecol Oncol. 2022. PMID: 37191644. doi:10.1016/j.ygyno.2022.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。